Earnings ·
LENZ Therapeutics reported second quarter 2026 financial results on August 11, 2026
LENZLENZ Therapeutics, Inc.
LENZ Therapeutics reported second quarter 2026 financial results on August 11, 2026. Total revenue was $5.5 million, comprising $1.7 million in product sales from approximately 27,000 packs of VIZZ and $3.8 million in license revenue, which included a $2.5 million regulatory milestone under the Théa agreement and $1.25 million in sublicense revenue from Everest Medicines for Greater China rights. The company reported a net loss of $31.9 million, or $1.02 per share, compared to a $14.9 million loss in the prior year period. Selling, general, and administrative expenses rose to $39.4 million due to launch investments in marketing and sales infrastructure. Cash, cash equivalents, and marketable securities totaled $220.0 million as of June 30, 2026. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ for the treatment of presbyopia.